Antibodies for Treating Cancer

Presents a compact and comprehensive introduction to a complex topic Intended for a broad readership, ranging from professionals and experts in the field to residents and medical students Illustrates key parts of the content using self-explanatory figures

Autorentext

Melvyn Little received his degree in chemistry and PhD in biochemistry from Bangor University, Wales and subsequently completed a Postdoc at the Max-Planck-Institute for Cell Biology in Wilhelmshaven, Germany. He has served as head of the Research Group "Recombinant Antibodies" at the German Cancer Research Center in Heidelberg and as an External Professor of Biochemistry at Heidelberg University. In addition, he was a Co-founder and Supervisory Board Member of the biotech firm Affitech in Oslo, Norway, as well as Founder and Management Board Member of the biotech firm Affimed in Heidelberg. His primary research interest is in the development of dual binding antibodies for recruiting killer immune cells to destroy tumor cells. Currently he is in retirement and a biotechnology consultant.

Inhalt

1 Life-saving antibodies history of immunization.- 2 Current approaches for immunising against cancer.- 3 Function and Structure of antibodies.- 4 Of mice and men - production of therapeutic antibodies.- 5 Novel modular antibodies.- 6 Antibodies as Magic Bullets.- 7 Mediation of tumor cell destruction.- 8 Engagement of immune killer cells.- 9 Approved antibodies for cancer therapy.- 10 Bringing therapeutic antibodies on the market.- 11 Future developments outlook. <p